Lasmiditan

• Acute Migraine Treatment
• Migraine with Aura
• Migraine without Aura
• Alternative to Triptans

Lasmiditan (Reyvow) is the first member of the "ditan" class — selective serotonin 5-HT1F receptor agonists — for acute treatment of migraine with or without aura in adults. Unlike triptans, lasmiditan does not constrict blood vessels, which makes it a meaningful option for patients with cardiovascular disease, prior stroke, peripheral vascular disease, or uncontrolled hypertension who cannot safely use triptans such as sumatriptan. It received FDA approval in 2019 and is a Schedule V controlled substance because of mild euphoric effects observed in human abuse-potential studies, and it carries a unique 8-hour driving restriction after each dose. For patients whose cardiovascular profile rules out the triptan class, lasmiditan and the gepant family (rimegepant and ubrogepant) together represent the most important advance in acute migraine therapy in over two decades.

Mechanism of Action

Lasmiditan binds with high affinity and selectivity to the 5-HT1F serotonin receptor subtype, which is expressed on trigeminal sensory neurons in the trigeminal ganglion and in the trigeminocervical complex of the brainstem. Activation of 5-HT1F receptors inhibits the release of CGRP and other inflammatory neuropeptides from peripheral and central trigeminal terminals, dampening the cascade that drives migraine pain and central sensitization. Critically, lasmiditan has minimal affinity for 5-HT1B receptors on cranial blood vessels — the receptors triptans engage to cause vasoconstriction. The absence of vasoconstrictive activity is what removes the cardiovascular contraindications that limit triptan use in patients with coronary artery disease, prior myocardial infarction, stroke, transient ischemic attack, peripheral vascular disease, hemiplegic migraine, basilar migraine, or uncontrolled hypertension. Because 5-HT1F receptors are also present in central pain pathways, lasmiditan crosses the blood-brain barrier and produces dose-dependent CNS depression — the mechanism behind its dizziness, sedation, and driving impairment. The drug reaches peak plasma concentration in about 2 hours and has a half-life of approximately 5.7 hours; food slightly delays absorption but does not affect overall exposure.

Clinical Use

Lasmiditan is approved for acute (not preventive) migraine in adults. It is most appropriate for patients with cardiovascular contraindications to triptans, those who have not responded to two or more triptans, or those who experience triptan-induced chest tightness or vasoconstrictive symptoms. Compared with the gepant class — rimegepant and ubrogepant — lasmiditan offers similar 2-hour pain freedom rates (about 28-32% versus 15-21% with placebo in pivotal trials) but a less favorable tolerability profile because of CNS effects, and gepants are generally preferred when both options are available and affordable. Patients with frequent migraines who require acute treatment more than 8-10 days per month should also be on a preventive such as galcanezumab, fremanezumab, erenumab, or an oral preventive — using acute treatment too often paradoxically worsens headaches via medication-overuse headache. The American Headache Society 2021 consensus statement explicitly recognizes lasmiditan as a preferred option when triptans are contraindicated or ineffective. Patients with migraine frequently have other related conditions — anxiety, depression, sleep disturbance, generalized anxiety disorder, and major depressive disorder — that warrant integrated care and may influence drug interactions because many psychiatric medications are serotonergic.

How to Take It

Lasmiditan tablets come in 50, 100, and 200 mg strengths and are taken at the first sign of a migraine attack — earlier dosing produces better results. Most clinicians start at 100 mg; if the first dose is poorly tolerated because of dizziness or sedation, the next attack can be tried at 50 mg, and if a 100 mg dose is well tolerated but ineffective, 200 mg can be used for the next attack. Only one dose may be taken in any 24-hour period — a second dose for the same attack is not recommended and is not supported by evidence of additional benefit. The tablet can be taken with or without food, swallowed whole with water. The most important counseling point: do not drive, ride a bicycle, or operate machinery for at least 8 hours after each dose, even if you feel back to normal earlier — formal driving simulator studies show measurable impairment for that full window. Plan ahead so you have transportation arranged, work flexibility, and a quiet place to rest. Avoid combining lasmiditan with alcohol or other CNS depressants such as benzodiazepines like lorazepam or alprazolam, opioids, or sedating antihistamines, because additive CNS depression can be marked. Like all acute migraine medications, lasmiditan should be limited to no more than 4 attacks per month or about 10 treatment days per month to avoid medication-overuse headache. Because lasmiditan is a Schedule V controlled substance, prescriptions may be limited in quantity and refill behavior compared with non-scheduled medications.

Monitoring and Follow-Up

Keep a headache diary noting attack frequency, time to relief after lasmiditan, and any side effects including dizziness, fatigue, paresthesia, sedation, and nausea. Acute medication use exceeding 10 days per month is a trigger to start or intensify preventive therapy. No routine blood work is required for lasmiditan itself, but baseline blood pressure and cardiovascular risk assessment guide the broader migraine treatment plan and help confirm the rationale for choosing lasmiditan over a triptan. Mild bradycardia has been reported; patients on heart-rate-lowering drugs (beta-blockers, calcium channel blockers, digoxin) deserve closer attention. Pulse may be checked in the office at follow-up. Cognitive screening at baseline and on follow-up is reasonable in older adults, who are more susceptible to CNS effects. Document any history of substance use disorder before starting given the controlled status. Insurance coverage for lasmiditan varies widely, and prior authorization or step therapy through one or more triptans is often required.

Special Populations

No dose adjustment is required for renal impairment or for mild to moderate hepatic impairment; severe hepatic impairment has not been studied. Older adults are more susceptible to dizziness, sedation, and falls — start at 50 mg and reassess after the first attack. Pregnancy data are limited; animal studies showed developmental toxicity at high doses, so use only when benefits clearly outweigh risks and only after discussing alternatives such as acetaminophen, antiemetics, and non-pharmacologic measures. Lactation data are absent, and given the CNS-active properties caution is warranted in nursing mothers. Patients with a history of substance use disorder should be counseled about the abuse potential, and lasmiditan should be avoided in patients actively using other serotonergic drugs without close supervision because of serotonin syndrome risk — common offenders include SSRIs like sertraline, escitalopram, fluoxetine, and paroxetine, SNRIs such as duloxetine and venlafaxine, MAOIs, tramadol, trazodone, and St. John's wort.

When to Contact Your Doctor

Call the office if migraines are increasing in frequency, lasmiditan is not providing reliable relief at maximum tolerated dose, you experience persistent dizziness or sedation lasting beyond the 8-hour window, or you develop new chest pain, palpitations, or shortness of breath. Seek emergency care for confusion, high fever, muscle rigidity, autonomic instability, agitation, hyperreflexia, or tremor — possible serotonin syndrome — especially if you take SSRIs, SNRIs, MAOIs, or other serotonergic drugs. The first migraine that feels qualitatively different from your usual pattern — sudden onset thunderclap, accompanied by neurologic deficit, fever, or following head trauma — warrants immediate evaluation regardless of medication taken.

A practical comparison may help: triptans remain first-line acute therapy for most patients with migraine because they are inexpensive, widely available, and effective, but their vasoconstrictive properties exclude many patients with cardiovascular risk. Gepants (rimegepant, ubrogepant) avoid vasoconstriction and lack the CNS depression of lasmiditan but may be more expensive and require prior authorization. Lasmiditan's unique advantage is that it has been studied directly in patients with stable cardiovascular disease and does not constrict coronary or cerebral arteries, making it the right choice when cardiovascular safety is paramount. Patients with chronic headaches often benefit from a layered approach combining preventive medication, acute therapy, and behavioral interventions including biofeedback, cognitive-behavioral therapy, and structured sleep hygiene as outlined in our sleep hygiene guide. Document attacks carefully — patterns reveal triggers (specific foods, hormonal phases, weather changes, sleep disruption) that can be modified.

For an individualized acute and preventive migraine plan, including a careful review of cardiovascular risk and serotonergic medication interactions, contact us or schedule a visit at Zimmer Medical Group.